Daiichi Sankyo Co., Ltd. in Japan, Oncoscience AG in Europe, Kuhnil Pharmaceutical Co. in South Korea and Innogene Kalbiotech in Southeast Asia have sub-licenses for nimotuzumab from CIMYM Inc., YM's majority-owned subsidiary. Cooperative trials have already been initiated with some of CIMYM's licensees and YM anticipates that the licensees will increasingly participate cooperatively to accelerate the rate of recruitment into trials of common interest, reducing the costs of development for each participant, permitting rapid recruitment and shortening the time to completion of clinical trials.
During Fiscal 2007:
- CIMYM BioSciences Inc. licensed the commercial rights for nimotuzumab
to Daiichi Sankyo Co., Ltd. for the Japanese market. The agreement
included a non-refundable up-front payment from Daiichi to the Company
of $16.2 million.
- YM BioSciences USA received clearance from the US Treasury Department
to import nimotuzumab into the US
- Daiichi Sankyo received clearance to initiate a clinical trial with
the drug in Japan.
- YM initiated enrollment for a Phase II colorectal cancer trial in
Canada. The first 50-patient cohort is expected to be completed in
calendar 2007 following which data on the primary endpoints, response
rate and safety, will be reported.
- YM received clearance to initiate a clinical trial in children with
inoperable recurrent, treatment-resistant brain cancer in Canada.
- YM reported successful regulatory review of the manufacturing of
- YM reported preclinical data separately confirming that nimotuzumab
binds to the EGF receptor and that it also potentiates radiotherapy in
non-small-cell lung cancer cells.
Subsequent to the end of the fiscal y
|SOURCE YM BioSciences Inc.|
Copyright©2007 PR Newswire.
All rights reserved